Trial Profile
Prevalence and clinical presentation of thyroid dysfunction associated with sunitinib therapy in renal cell carcinoma patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 21 Aug 2015 New trial record